Resistell AG, a leader in phenotypic nanomotion technology for measuring living cells, based in Muttenz, Switzerland, has taken another major step to achieving its vision by closing a first tranche of its series B financing round raising CHF 8.5m from new and existing investors. Investors include EIC Fund, TRUMPF Venture, OCCIDENT, Zürcher Kantonalbank, Launchpad, and private investors. The funds will be used to complete the company’s clinical trials for antibiotic susceptibility testing (AST) and for market entry of its R&D device Phenotech Research.

VISCHER acts as legal advisor to Resistell AG in the series B financing round. The VISCHER team includes Christian Wyss (Partner, Corporate/M&A), Timothy Woodtli (Associate, Corporate/M&A), Michael Maurer (Associate, Corporate/M&A), Bettina Fischer (Junior Associate, Corporate/M&A), Adrian Briner (Managing Associate, Tax) and Jannick Walleser (Associate, Tax).